Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06557330 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 29, 2027 to Sep 29, 2027
    • Start date: Dec 2024 to Jun 2025
    • Study completion date: Sep 30, 2027 to Mar 30, 2028
    v4
  2. Start date: Sep 2024 to Dec 2024v3
  3. Start date: Aug 27, 2024 to Sep 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II pilot, single arm, open label study designed to assess the efficacy, safety, and feasibility of MRD adapted duration of BR for untreated or R/R iNHL.
Trial Details
NCT Number NCT06557330
Lead Sponsor Fox Chase Cancer Center
Collaborators: Adaptive Biotechnologies
Conditions
(from sponsor)		 Lymphoma, Indolent Non-hodgkin Lymphoma
Related terms Lymphoma
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov